Skip to main content

Table 1 Enrolled patients

From: Intraoperative neuromonitoring for function-guided resection differs for supratentorial motor eloquent gliomas and metastases

  

Metastases

Gliomas

Sex

male

32 (61.0 %)

62 (59.1 %)

 

female

21 (39.0 %)

43 (40.9 %)

Age (years)

Mean

61.0.

53.3

Median

63.0

53.7

Min

24.2

16.0

Max

89.4

84.3

Type of primary cancer/WHO-grade

lung cancer

17 (30.0 %)

 

breast cancer

12 (21.0 %)

 

melanoma

5 (9.0 %),

 

colon

4 (7.0 %)

 

renal cancer

4 (7.0 %)

 

others

14 (26.0 %)

 

WHO I

-

3 (2.7 %)

WHOII

-

17 (15.2 %)

WHO III

-

22 (19.6 %)

WHO IV

-

70 (62.5 %)

Number

1

32 (57.0 %)

103 (100 %)

2

10 (18.0 %)

3

6 (11.0 %)

>3

8 (14.0 %)

location of tumor

frontodorsal/SMA

27.0 %

32.0 %

precentral gyrus

37.0 %

16.0 %

postcentral gyrus

14.0 %

18.0 %

CST

22.0 %

34.0 %

preoperative status

paresis

32 (57.0 %)

35 (31.3 %)

seizures

17 (30.0 %)

24 (21.4 %)

dizziness

5 (9.0 %)

-

incidental

2 (4 %)

-

hemihypesthesia

-

19 (17.0 %)

MEP changes

Intraoperative stable posthoc analysis >50 % amplitude loss

29 (54.7 %)

73 (65.2 %)

none (stable)

32 (60.0 %)

85 (80.1 %)

reversible

7 (13.0 %)

9 (8.6 %)

irreversible

14 (27.0 %)

11 (10.3 %)

>80 % amplitude loss

none (stable)

30 (56.6 %)

24 (22.9 %)

reversible

20 (37.7 %)

70 (66.7)

irreversible

3 (5.7 %)

11 (10.3 %)

surgery-related deficits

temporary

5 (9.4 %)

19 (18.1 %)

permanent

7 (12.5 %)

14 (12.5 %)

Follow-up (months)

Mean ± SD

2.9 ± 4.5

9.7 ± 10.5

Median

0.7 months

6.1

Min

0.1

0.5

Max

20.1

40.6

  1. Overview of all enrolled patients including primary tumor, MEP changes intraoperatively, and surgery-related deficits